The U.S. Food and Drug Administration has issued a labeling approval (status "AP") for the generic drug application ANDA078251 submitted by Glenmark Pharmaceuticals Inc., USA.
The approved product is carvedilol, an oral tablet classified as a prescription drug. Four tablet strengths are listed: 3.125 mg (product number 001), 6.25 mg (002), 12.5 mg (003) and 25 mg (004). The associated NDC codes span 68462‑162‑01 to 68462‑165‑10.
Labeling submissions for this ANDA have been approved on multiple dates, most recently on 2023‑11‑01 (submission number 19). Earlier approvals were recorded on 2007‑07‑13, 2014‑09‑26 and 2013‑05‑07.
Actualizaciones regulatorias25 sept 2026•1 min de lectura
FDA Approves Glenmark’s Carvedilol Generic Tablets (ANDA078251)
The FDA has granted labeling approval for Glenmark Pharmaceuticals’ generic carvedilol tablets (ANDA078251), available in 3.125 mg, 6.25 mg, 12.5 mg and 25 mg oral dosage forms.
Recopilado por el equipo de PharmaCountry · Fuente: FDA.gov
Calificaciones
(0)
(0)
(0)
(0)
(0)
Más artículos
Ver todos los artículosInvestigación e Informes
Global Finished Dosage Manufacturing Landscape 2026
5 oct 2026
Actualizaciones regulatoriasKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 sept 2026
AnálisisPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 sept 2026
Deja tu valoración